Please assess the completion status of the following clinical trial:

Trial Title: Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women with confirmed HIV-1 infection (positive Western blot or plasma HIV-1 RNA \>1,000 copies/ml)~* Gestational age higher than 28 weeks~* Age equal or higher than 15 years~* HIV-1 plasma viral load ≥ 1,000 copies of HIV-1 RNA/ml~Exclusion Criteria:~* Age lower than 15 years~* Undetectable plasma viral load at screening~* Previous use of RAL

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Raltegravir (Type: EXPERIMENTAL): Use of Raltegravir plus backbone treatment for pregnant women
- Lopinavir/Ritonavir (Type: ACTIVE_COMPARATOR): Use of standard PI treatment (Lopinavir/r) plus backbone treatment for pregnant women

Based on this trial design, predict the completion outcome and termination type (if applicable).